Overview
- Pfizer updated 2026 revenue guidance to $60.5–$62.5 billion, a roughly 39% drop from its 2022 peak, and its shares trade near $28 as investors digest the reset.
- The company increased research spending about 13% in the first half of 2026 even as management forecasts roughly a 2% decline in full‑year revenue.
- Pfizer is pursuing manufacturing and operational programs targeting about $9.7 billion in cumulative net savings through 2029, including an incremental $2.7 billion of cuts from 2027–2029.
- Valuation readings diverge sharply with a 9.43x non‑GAAP 2026 P/E based on expected EPS of $2.98 versus a 36.9x GAAP P/E, and Wall Street holds a Moderate Buy consensus with an average price target near $28.46.
- The company is banking on oncology, mRNA platforms, antibody‑drug conjugates and a Lyme vaccine candidate to drive high single‑digit revenue CAGR after 2028 while dividend income and execution on cost and clinical milestones remain key risks for investors.